Shots: Axovant acquires WW development and commercialization rights for AXO-AAV-GM1 and AXO-AAV-GM2 Program and will make payments to University of Massachusetts The focus of the agreement is to develop functional copies of HEXA, HEXB & GLB1 genes encoding the certain enzymes to treat Gm1 Gangliosidosis, Tay-Sachs and Sandhoff Diseases AXO-AAV-GM1 program is initiated for GLB1 gene using AAV vector for […]Read More
Tags : Neurodegenerative Genetic Disorders
Latest Posts
Categories
Related Topics
AbbVie
Acceptance
Acquire
Adults
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Collaborate
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Merck
Novartis
P-III
patients
Pfizer
receives
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
the US FDA
Treat
Treatment
US